The myeloid Src-family kinases Hck, Lyn and Fgr have been independently described as relevant AML drug targets, and inhibition of these kinases is also a promising strategy for AML treatment [19,20,22,34]. This evidence concerns the gene FGR and acute myeloid leukemia.